Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7386 plus pembrolizumab in previously treated selected advanced solid tumors
jRCT2031210405Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of e7386 and pembrolizumab in melanoma, colorectal cancer (CRC) and hepatocellular carcinoma (HCC), sponsored by Eisai Co., Ltd. Primary endpoints: Number of participants with dose-limiting toxicities, Number of participants with treatment-emergent adverse events and 1 more. Started Dec 2021; status: completed.
02
Drugs
e7386pembrolizumab
03
Conditions
melanomacolorectal cancer (CRC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2031210405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210405.